Browsing by Author "Chen, Liang"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study(2021) Wang, Minggui; Earley, Michelle; Chen, Liang; Hanson, Blake M.; Yu, Yunsong; Liu, Zhengyin; Salcedo, Soraya; Cober, Eric; Li, Lanjuan; Kanj, Souha S.; Gao, Hainv; Munita, José; Ordoñez, Karen; Weston, Greg; Satlin, Michael J.; Valderrama-Beltrán, Sandra L.; Marimuthu, Kalisvar; Stryjewski, Martin E.; Komarow, Lauren; Luterbach, Courtney; Marshall, Steve H.; Rudin, Susan D.; Manca, Claudia; Paterson, David L.; Doi, Yohei; Patel, Robin; Kreiswirth, Barry N.; Bonomo, Robert A.; Chambers, Henry F.; Fowler, Jr. Vance G.; Arias, Cesar A.; Duin, David van; Multi-Drug Resistant Organism Network InvestigatorsBackground: Carbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA. Methods: CRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227. Findings: 1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died. Interpretation: Among patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales. Funding: National Institutes of Health.Publication Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study(2023) Reyes, Jinnethe; Komarow, Lauren; Chen, Liang; Ge, Lizhao; Hanson, Blake; Cober, Eric; Herc, Erica; Alenazi, Thamer; Kaye, Keith; Garcia, Julia; Li, Lanjuan; Kanj, Souha; Liu, Zhengyin; Oñate, Jose; Salata, Robert; Marimuthu, Kalisvar; Gao, Hainv; Zong, Zhiyong; Valderrama, Sandra; Yu, Yunsong; Tambyah, Paul; Weston, Gregory; Salcedo, Soraya; Abbo, Lillian; Xie, Qing; Ordoñez, Karen; Wang, Minggui; Stryjewski, Martin; Munita, Jose M.; Paterson, David; Evans, Scott; Hill, Carol; Baum, Keri; Bonomo, Robert; Kreiswirth, Barry; Virginia, Maria; Pate, Robin; Arias, Cesar; Chambers, Henry; Fowler,Vance; Doi, Yohei; Van Duin, David; Satlin, Michael; Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network InvestigatorsBackground: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA. Methods: We conducted an observational, prospective cohort study of CRPA isolated from bloodstream, respiratory, urine, or wound cultures of patients at 44 hospitals (10 countries) between Dec 1, 2018, and Nov 30, 2019. Clinical data were abstracted from health records and CRPA isolates were whole-genome sequenced. The primary outcome was 30-day mortality from the day the index culture was collected. We compared outcomes of patients with CRPA infections by infection type and across geographic regions and performed an inverse probability weighted analysis to assess the association between carbapenemase production and 30-day mortality. Findings: We enrolled 972 patients (USA n=527, China n=171, south and central America n=127, Middle East n=91, Australia and Singapore n=56), of whom 581 (60%) had CRPA infections. 30-day mortality differed by infection type (bloodstream 21 [30%] of 69, respiratory 69 [19%] of 358, wound nine [14%] of 66, urine six [7%] of 88; p=0·0012) and geographical region (Middle East 15 [29%] of 52, south and central America 20 [27%] of 73, USA 60 [19%] of 308, Australia and Singapore three [11%] of 28, China seven [6%] of 120; p=0·0002). Prevalence of carbapenemase genes among CRPA isolates also varied by region (south and central America 88 [69%] of 127, Australia and Singapore 32 [57%] of 56, China 54 [32%] of 171, Middle East 27 [30%] of 91, USA ten [2%] of 527; p<0·0001). KPC-2 (n=103 [49%]) and VIM-2 (n=75 [36%]) were the most common carbapenemases in 211 carbapenemase-producing isolates. After excluding USA patients, because few US isolates had carbapenemases, patients with carbapenemase-producing CRPA infections had higher 30-day mortality than those with non-carbapenemase-producing CRPA infections in both unadjusted (26 [22%] of 120 vs 19 [12%] of 153; difference 9%, 95% CI 3-16) and adjusted (difference 7%, 95% CI 1-14) analyses.Interpretation: The emergence of different carbapenemases among CRPA isolates in different geographical regions and the increased mortality associated with carbapenemase-producing CRPA infections highlight the therapeutic challenges posed by these organisms. Funding: National Institutes of Health.